Results 161 to 170 of about 174,955 (289)

Hyperparathyroidism: historical milestones and modern therapeutic strategies. [PDF]

Wien Klin Wochenschr
Niederle B, Niederle MB.
europepmc   +1 more source

Multiple Oral and Eyelid Nodules in a Pediatric Patient

Oral Diseases, EarlyView.
Caique Mariano Pedroso, Paulo Victor Mendes Penafort, Patrícia Vitor de Souza, Fernanda M. Pascon, Regina Maria Punppin‐Rontani, Beatriz Frolini Paulo Cherve, Rachel Marinho Robim, Regina Maria Holanda de Mendonça, Marcio Ajudarte Lopes, Pablo Agustin Vargas, Alan Roger Santos‐Silva   +10 more
wiley   +1 more source

Molecular pathophysiology of chronic kidney disease–mineral and bone disorder: Focus on the fibroblast growth factor 23–Klotho axis and bone turnover dynamics

Experimental Physiology, EarlyView.
Abstract Chronic kidney disease–mineral and bone disorder (CKD‐MBD) is a major complication of chronic kidney disease (CKD), characterized by disruptions in mineral metabolism, abnormal bone turnover and vascular calcification, which collectively increase the risk of fractures and cardiovascular disease.
Alief Waitupu, Laras Pratiwi, Henry Sutanto, Djoko Santoso, Decsa Medika Hertanto   +4 more
wiley   +1 more source

Clinical and Biochemical Correlates of Parathyroid Gland Burden in Patients Undergoing Parathyroidectomy for Secondary Hyperparathyroidism: A Retrospective Observational Study. [PDF]

J Clin Med
Keyif MF, Destek S.
europepmc   +1 more source

Hypoparathyroidism: a brief historical overview for clinicians. [PDF]

Front Endocrinol (Lausanne)
Díez JJ.
europepmc   +1 more source

Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism

Therapeutic Apheresis and Dialysis, Volume 30, Issue 3, Page 309-322, June 2026.
ABSTRACT Secondary hyperparathyroidism (SHPT) is a common complication in patients receiving maintenance dialysis, driven by calcium and phosphate metabolism disturbances. Calcimimetics are central to the management of SHPT by enhancing calcium‐sensing receptor sensitivity and reducing parathyroid hormone secretion.
Fumihiko Koiwa, Daisuke Honda, Seigo Akari, Tadao Akizawa   +3 more
wiley   +1 more source

The John J. Larkin, Jr. Memorial Grant in aid for Medical Research Established by the Saint Luke Guild of Catholic Physicians of Boston [PDF]

, 1964
Kane, Charles A.
core   +1 more source

Dehnel's Phenomenon in Mammals

Mammal Review, Volume 56, Issue 2, June 2026.
Some small mammals, which remain active year‐round, undergo reversible reductions in body size, braincase height, and the mass of internal organs, including the brain, from summer to winter. It is called Dehnel's phenomenon. In this review, we summarise knowledge of the mechanisms, adaptive value, and genetic basis of the phenomenon, and show how new ...
Jan R. E. Taylor, Cecilia Baldoni, Dina K. N. Dechmann   +2 more
wiley   +1 more source

Unanticipated remission of primary hyperparathyroidism following cinacalcet. [PDF]

JCEM Case Rep
Ramadan S, Haddady S.
europepmc   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, Volume 78, Issue 5, Page 1176-1183, May 2026.
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source